Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.78 ^USD	+0.53%		+2.16%	+42.64%

Mar. 20	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Mar. 20	Sector Update: Health Care Stocks Down Wednesday Afternoon	MT

Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 19, 2024 at 04:01 pm EDT

Design Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 11.84 million compared to USD 17.34 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.31 a year ago.

Latest news about Design Therapeutics, Inc.

Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	Mar. 20	MT
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	Mar. 20	MT
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk	Nov. 14	MT
Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating	Nov. 14	MT
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Insider Buy: Design Therapeutics	23-08-31	MT
Design Therapeutics, Inc. Announces Principal Financial Officer Changes	23-08-25	CI
Design Therapeutics, Inc. Announces CEO Changes	23-08-25	CI
Design Therapeutics, Inc. Announces Management Changes	23-08-25	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
Financial Sector Woes, Lackluster Chinese Data Weigh on US Equity Markets	23-08-15	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	23-08-15	MT
Sector Update: Health Care Stocks Slip Pre-Bell Tuesday	23-08-15	MT
Sentiment Subdued After Downbeat China Data, Pushing US Equity Futures Lower Pre-Bell	23-08-15	MT
Sector Update: Health Care	23-08-15	MT
SVB Downgrades Design Therapeutics to Market Perform From Outperform, Cuts Price Target to $6 From $22	23-08-15	MT
Top Premarket Decliners	23-08-15	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	23-08-15	MT
RBC Downgrades Design Therapeutics to Sector Perform From Outperform, Cuts Price Target to $7 From $23 Amid 'Limited Near-Term Catalysts,' Keeps Speculative Risk	23-08-15	MT

Chart Design Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.78 USD

Average target price

4.667 USD

Spread / Average Target

+23.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DESIGN THERAPEUTICS, INC.	+42.64%	214M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.37%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research